Effect of short-acting beta blocker on the cardiac recovery after cardiopulmonary bypass

Abstract

The objective of this study was to investigate the effect of beta blocker on cardiac recovery and rhythm during cardiac surgeries. Sixty surgical rheumatic heart disease patients were received esmolol 1 mg/kg or the same volume of saline prior to removal of the aortic clamp. The incidence of cardiac automatic re-beat, ventricular fibrillation after reperfusion, the heart rate after steady re-beat, vasoactive drug use during weaning from bypass, the posterior parallel time and total bypass time were decreased by esmolol treatment. In conclusion: Esmolol has a positive effect on the cardiac recovery in cardiopulmonary bypass surgeries.

Meta-analysis of the benefit of beta-blockers for the reduction of isolated atrial fibrillation incidence after cardiac surgery

“…The final 21 papers were reviewed in full text, and the following were excluded due to the following reasons: 1 study did not have a control group, 6 1 study used sotalol as its study drug, 7 1 study did not segregate outcomes between isolated AF and other forms of SVT, 8 and 1 study focused on the combination therapy of b-blocker and magnesium. 9 Eventually, 17 RCTs, 5 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 fully satisfying our predefined inclusion criteria, were selected from papers published in varying years. Figure 1 is the Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols flow chart of our study as per established 2009 guidelines.…”

“…All trials focused on isolated POAF for patients undergoing cardiac surgery. Eleven trials only included patients who underwent coronary artery bypass grafting (CABG) surgery, 10 , 11 , 12 , 14 , 16 , 17 , 18 , 19 , 20 , 21 , 22 whereas 6 other trials included patients with a variety of surgeries (CABG and valve). 5 , 13 , 15 , 23 , 24 , 25 Study characteristics are summarized in Table 1 .…”

“…The final 21 papers were reviewed in full text, and the following were excluded due to the following reasons: 1 study did not have a control group, 6 1 study used sotalol as its study drug, 7 1 study did not segregate outcomes between isolated AF and other forms of SVT, 8 and 1 study focused on the combination therapy of b-blocker and magnesium. 9 Eventually, 17 RCTs, 5,[10][11][12][13][14][15][16][17][18][19][20][21][22][23][24][25] fully satisfying our predefined inclusion criteria, were selected from papers published in varying years. Figure 1 The included studies were published between 1983 and 2020 and are from 9 different countries (United States, United Kingdom, Germany, Turkey, Austria, Japan, China, Brazil, Australia) ( Table 1).…”

“…5,11,12,19 Starting dose of b-blocker was similarly varied. Among studies with IV administration, dosage ranged from <2 mg/kg/min (n ¼ 1), 5 2 mg/kg/min (n ¼ 4), 5,17,18,24 >2 mg/kg/min (n ¼ 5), 13,19,20,22,25 1 mg (n ¼ 1), 10 and <50 mg/d (n ¼ 1). 23 In contrast, with regards to oral administration, dosage ranged from<50 mg/d (n ¼ 1), 11 50 mg/d (n ¼ 2), 14,16 and >50 mg/d (n ¼ 3).…”

Esmolol Administration for the Treatment of Refractory Ventricular Fibrillation

“…However, ischemia-reperfusion injury complicated with defibrillation damage deteriorates myocardial functions. Amiodarone, lidocaine, and beta-adrenergic blockers have been added to the cardioplegia solutions for the prevention of reperfusion VF (1)(2)(3)(4). Beta blockers have many beneficial effects on myocardial cells.…”